Abstract |
Recombinant human acid sphingomyelinase (rhASM) is being developed as an enzyme replacement therapy for patients with acid sphingomyelinase deficiency ( Niemann-Pick disease types A and B), which causes sphingomyelin to accumulate in lysosomes. In the acid sphingomyelinase knock-out (ASMKO) mouse, intravenously administered rhASM reduced tissue sphingomyelin levels in a dose-dependent manner. When rhASM was administered to normal rats, mice, and dogs, no toxicity was observed up to a dose of 30mg/kg. However, high doses of rhASM≥10mg/kg administered to ASMKO mice resulted in unexpected toxicity characterized by cardiovascular shock, hepatic inflammation, adrenal hemorrhage, elevations in ceramide and cytokines (especially IL-6, G-CSF, and keratinocyte chemoattractant [KC]), and death. The toxicity could be completely prevented by the administration of several low doses (3mg/kg) of rhASM prior to single or repeated high doses (≥20mg/kg). These results suggest that the observed toxicity involves the rapid breakdown of large amounts of sphingomyelin into ceramide and/or other toxic downstream metabolites, which are known signaling molecules with cardiovascular and pro-inflammatory effects. Our results suggest that the nonclinical safety assessment of novel therapeutics should include the use of specific animal models of disease whenever feasible.
|
Authors | James M Murray, Anne Marie Thompson, Allison Vitsky, Michael Hawes, Wei-Lien Chuang, Joshua Pacheco, Stephen Wilson, John M McPherson, Beth L Thurberg, Kenneth P Karey, Laura Andrews |
Journal | Molecular genetics and metabolism
(Mol Genet Metab)
Vol. 114
Issue 2
Pg. 217-25
(Feb 2015)
ISSN: 1096-7206 [Electronic] United States |
PMID | 25092414
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Ceramides
- Cytokines
- Recombinant Proteins
- Sphingomyelins
- Sphingomyelin Phosphodiesterase
|
Topics |
- Administration, Intravenous
- Adrenal Glands
- Animals
- Ceramides
(blood, metabolism)
- Cytokines
(blood, immunology)
- Disease Models, Animal
- Dogs
- Drug Evaluation, Preclinical
- Enzyme Replacement Therapy
- Female
- Liver
(metabolism, pathology)
- Lysosomes
(metabolism)
- Macaca fascicularis
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Niemann-Pick Disease, Type A
(drug therapy, metabolism)
- Rats
- Recombinant Proteins
(administration & dosage, toxicity)
- Sphingomyelin Phosphodiesterase
(administration & dosage, deficiency, toxicity)
- Sphingomyelins
(metabolism)
|